Ocular Therapeutix (OCUL) Receivables - Net (2013 - 2026)

Ocular Therapeutix has reported Receivables - Net for 14 years, with the latest figure at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 3.47% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 3.47% YoY), and the FY2025 full-year result was $30.6 million, down 5.37% from the prior year.
• Receivables - Net for Q1 2026 stood at $24.3 million, down from $30.6 million in the prior quarter.
• The five-year high for Receivables - Net was $32.4 million in Q4 2024, with the low at $19.8 million in Q3 2022.
• Average Receivables - Net over 5 years is $26.1 million, with a median of $26.2 million recorded in 2023.
• Year-over-year, Receivables - Net jumped 70.25% in 2022 and dropped 8.98% in 2023.
• Tracing OCUL's Receivables - Net over 5 years: stood at $21.3 million in 2022, then advanced by 22.76% to $26.2 million in 2023, then increased by 23.72% to $32.4 million in 2024, then dropped by 5.37% to $30.6 million in 2025, then retreated by 20.56% to $24.3 million in 2026.
• The last three Receivables - Net figures came in at $24.3 million (Q1 2026), $30.6 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.

Peer Comparison